Sung Hye Kim

Title: Innovations of Sung Hye Kim

Introduction

Sung Hye Kim is a notable inventor based in Gyeonggi-do, South Korea. She has made significant contributions to the field of pharmaceuticals, particularly in the development of novel compounds for cancer treatment. Her work focuses on innovative solutions that address critical health challenges.

Latest Patents

Sung Hye Kim holds a patent for a pyridine derivative that inhibits RAF kinase and vascular endothelial growth factor receptor. This invention includes a method for preparing the compound, a pharmaceutical composition containing it, and its various uses. The pyridine derivative is designed to inhibit Raf kinase (B-Raf, Raf-1, or B-RafV600E) and VEGFR2, which are involved in angiogenesis. This innovation has potential applications in the prevention or treatment of several types of cancer, including melanoma, colorectal cancer, prostate cancer, thyroid cancer, lung cancer, pancreatic cancer, and ovarian cancer, particularly those induced by RAS mutation.

Career Highlights

Throughout her career, Sung Hye Kim has worked with esteemed organizations, including the Incheon University Industry Academic Cooperation Foundation and Samjin Pharmaceutical Co., Ltd. Her experience in these institutions has allowed her to advance her research and contribute to the pharmaceutical industry.

Collaborations

Sung Hye Kim has collaborated with notable colleagues, including Eui Hwan Cho and Hee Jong Shin. These partnerships have facilitated the exchange of ideas and expertise, enhancing the impact of her work in the field.

Conclusion

Sung Hye Kim's innovative contributions to cancer treatment through her patented pyridine derivative exemplify her commitment to advancing medical science. Her work continues to inspire future research and development in pharmaceuticals.